The Birmingham trial of the O’Malley light coagulator

V. MYSKA AND K. RUBINSTEIN

Birmingham

During the months of April and May, 1972, thirty consecutive cases from the Medical Ophthalmology Clinic, Birmingham and Midland Eye Hospital, requiring light coagulation were treated with the O’Malley Log 2 portable xenon light coagulator – a product of Clinitex Inc., Beverley, Mass. (Figs 1 and 2). The instrument represents the first attempt...
at a long overdue miniaturisation of light coagulation equipment, and in particular an improvement on its manoeuvrability. For the last 20 years the standard equipment used in this hospital has been the Zeiss (Oberkochen) machine, and the new instrument is necessarily compared with this.

**Instrument specifications**

1. Dimension – 17½” × 14½” × 4”; weight – 50lb.; reach of articulated arm – 41”
2. The power source is by simple mains connection (115 or 220 volts) with built-in voltage regulator. No special electrical installations are necessary
3. Ophthalmoscope head manoeuvrability achieved by suspension angle-poise fitting and comparable with standard battery direct ophthalmoscope
4. Aperture sizes – 2°, 3°, 4°, 5°, and 6°
5. Diameter of light beam in the pupil: maximum 8.5 mm.
6. Range of power control: 1 to 10
7. Pre-selected time controls from 0.1 to 3 secs., allowing continuous precise adjustment
8. 3-digit application counter
9. Observation field of 25° with defined target area.

**Clinical material**

The thirty patients treated with the O’Malley light coagulator were affected by diabetic retinopathy (19 cases), exudative senile maculopathy (4 cases), circinate retinopathy (3 cases), central serous retinopathy (2 cases), malignant melanoma (1 case).

In 22 cases the aperture used was 3°; the largest aperture required for sufficient reaction was 6°, and this was in the case of a large peripheral horseshoe tear of the retina. In cases of central serous retinopathy (Fig. 3) and close paramacular applications in diabetic retinopathy (Fig. 4) aperture 2°.
was preferred. In the case of a malignant melanoma of the choroid aperture 3°, power 6, and exposure time 2 sec. were used effectively (Fig. 5, opposite).

The average exposure time was 1·0–1·5 sec., and the maximum was 2 sec. The number of applications required varied from three (cases of central serous retinopathy) to 202 (peripheral pattern bombing in diabetic retinopathy). The maximum number of applications in one (2½-hr) session was 320 (3 patients), with which the cooling system of the machine, although a little noisy, seemed to cope adequately. A total of 1,482 applications has been made with the machine without technical difficulties.
Conclusions

There are several factors in favour of the O'Malley light coagulator as compared with the Oberkochen instrument:

(a) Much better manoeuvrability of the ophthalmoscope.

(b) The illumination of the fundus is more even than in the Zeiss instrument, where a very highly illuminated target focus affects the operator's light adaptation and makes the orientation in reference to the rest of the fundus very difficult, especially with small apertures.

(c) It was found that aperture $2^\circ$ was a more useful size than the choice between the apertures $1.5^\circ$ or $3^\circ$ in the Zeiss coagulator when treating macular or paramacular lesions.

(d) The time pre-selectors and counting device, although not essential, were appreciated.

(e) The price is much lower.

At any selected aperture the power setting required for sufficient reactions left plenty in reserve. The power output is in the range of the green scale of the Zeiss machine but including the first setting of the red scale. More power may be necessary in cases of, e.g. hazy media or perhaps retinoblastoma, with which we had no experience in the present series. It is felt, however, that by prolonging the time of application an equivalent light energy would be delivered in such cases.
The Birmingham trial of the O'Malley light coagulator.

V Myska and K Rubinstein

doi: 10.1136/bjo.57.3.206

Updated information and services can be found at:
http://bjo.bmj.com/content/57/3/206.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/